You are here

  • Home
  • Archive
  • Volume 11, Issue 10
  • First-in-human phase I/Ib study of NIZ985, a recombinant heterodimer of IL-15 and IL-15Rα, as a single agent and in combination with spartalizumab in patients with advanced and metastatic solid tumors

Citation Tools

Article menu
Clinical/translational cancer immunotherapy
Original research
First-in-human phase I/Ib study of NIZ985, a recombinant heterodimer of IL-15 and IL-15Rα, as a single agent and in combination with spartalizumab in patients with advanced and metastatic solid tumors

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:
Leidner R, Conlon K, McNeel DG, et al
First-in-human phase I/Ib study of NIZ985, a recombinant heterodimer of IL-15 and IL-15Rα, as a single agent and in combination with spartalizumab in patients with advanced and metastatic solid tumors
Journal for ImmunoTherapy of Cancer 2023;11:e007725. doi: 10.1136/jitc-2023-007725